BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 26054751)

  • 1. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
    Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
    Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
    Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
    Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
    Dai L; Smith CD; Foroozesh M; Miele L; Qin Z
    Int J Cancer; 2018 May; 142(10):2153-2162. PubMed ID: 29277894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
    Guan S; Liu YY; Yan T; Zhou J
    Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
    Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
    Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
    Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
    Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
    Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
    Zhou J; Chen J; Yu H
    Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
    Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
    Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.
    Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M
    Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer.
    Liu W; Ning J; Li C; Hu J; Meng Q; Lu H; Cai L
    Tumour Biol; 2016 May; 37(5):6331-6. PubMed ID: 26628299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5.
    Liang Y; Xu W; Liu S; Chi J; Zhang J; Sui A; Wang L; Liang Z; Li D; Chen Y; Niu H
    Cell Physiol Biochem; 2018; 45(5):2054-2070. PubMed ID: 29533936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission.
    Wu B; Xiong J; Zhou Y; Wu Y; Song Y; Wang N; Chen L; Zhang J
    Arch Biochem Biophys; 2020 Oct; 692():108539. PubMed ID: 32777260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
    Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
    Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
    LeBlanc FR; Pearson JM; Tan SF; Cheon H; Xing JC; Dunton W; Feith DJ; Loughran TP
    Br J Haematol; 2020 Aug; 190(3):405-417. PubMed ID: 32124438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells.
    Ouyang W; Yang C; Zhang S; Liu Y; Yang B; Zhang J; Zhou F; Zhou Y; Xie C
    Int J Oncol; 2013 Feb; 42(2):699-711. PubMed ID: 23258590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Qian Y; Zhang L; Ma H; Jiang X
    Int J Nanomedicine; 2012; 7():1449-60. PubMed ID: 22619505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.